SMAD1 and non-small cell lung carcinoma: We found that higher expression of ILF3-AS1 (Figures 9D, G) or SMAD1 (Figures 9E, H) was significantly correlated with shorter overall survival time for both NSCLC and LUAD patients (Figures 9F, I).